Kalvista Pharmaceuticals (NASDAQ:KALV) posted its earnings results on Monday. The specialty pharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01), MarketWatch Earnings reports. Kalvista Pharmaceuticals had a negative net margin of 229.45% and a negative return on equity of 31.21%.
Shares of KALV stock opened at $13.99 on Tuesday. Kalvista Pharmaceuticals has a 12-month low of $5.61 and a 12-month high of $18.96. The firm has a market capitalization of $250.46 million, a price-to-earnings ratio of -8.53 and a beta of 2.44. The firm has a fifty day moving average of $12.38 and a 200-day moving average of $11.13.
Several research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating on shares of Kalvista Pharmaceuticals in a research report on Thursday, July 2nd. Zacks Investment Research lowered shares of Kalvista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, July 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 target price on shares of Kalvista Pharmaceuticals in a report on Wednesday, July 1st. Finally, ValuEngine lowered shares of Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 1st. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $22.67.
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Further Reading: What are the benefits of investing in REITs?
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.